Lucky No. 35? Sarepta And BioMarin Settle Global Patent Disputes

A legal settlement with BioMarin means that Sarepta doesn't have to worry anymore about the potential to infringe patents related to exon-skipping DMD therapies. Meanwhile, BioMarin gains some compensation for its ill-fated Prosensa buy.

Handshake of businessmen

Sarepta Therapeutics Inc. will pay BioMarin Pharmaceutical Inc. $35m up front, certain milestone fees and single-digit royalties in a patent settlement and license agreement related to exon-skipping therapies for Duchenne muscular dystrophy (DMD), reducing Sarepta's risk related to Exondys 51 (eteplirsen) and its other DMD product candidates, especially in ex-US markets.

The agreements give BioMarin some compensation for its ill-fated 2014 acquisition of Prosensa Holding BV, which eventually resulted in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.